The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection

Simple item page
dc.citation.articleNumbere0011519
dc.citation.issueNumber11
dc.citation.journalTitlePLOS Neglected Tropical Diseases
dc.citation.volumeNumber17
dc.contributor.authorNguyen, Duc Minh
dc.contributor.authorPoveda, Cristina
dc.contributor.authorPollet, Jeroen
dc.contributor.authorGusovsky, Fabian
dc.contributor.authorBottazzi, Maria Elena
dc.contributor.authorHotez, Peter J.
dc.contributor.authorJones, Kathryn Marie
dc.date.accessioned2024-05-03T15:51:11Z
dc.date.available2024-05-03T15:51:11Z
dc.date.issued2023
dc.description.abstractBackground Chagas disease, chronic infection with Trypanosoma cruzi, mainly manifests as cardiac disease. However, the liver is important for both controlling parasite burdens and metabolizing drugs. Notably, high doses of anti-parasitic drug benznidazole (BNZ) causes liver damage. We previously showed that combining low dose BNZ with a prototype therapeutic vaccine is a dose sparing strategy that effectively reduced T. cruzi induced cardiac damage. However, the impact of this treatment on liver health is unknown. Therefore, we evaluated several markers of liver health after treatment with low dose BNZ plus the vaccine therapy in comparison to a curative dose of BNZ. Methodology Female BALB/c mice were infected with a bioluminescent T. cruzi H1 clone for approximately 70 days, then randomly divided into groups of 15 mice each. Mice were treated with a 25mg/kg BNZ, 25μg Tc24-C4 protein/ 5μg E6020-SE (Vaccine), 25mg/kg BNZ followed by vaccine, or 100mg/kg BNZ (curative dose). At study endpoints we evaluated hepatomegaly, parasite burden by quantitative PCR, cellular infiltration by histology, and expression of B-cell translocation gene 2(BTG2) and Peroxisome proliferator-activated receptor alpha (PPARα) by RT-PCR. Levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were quantified from serum. Results Curative BNZ treatment significantly reduced hepatomegaly, liver parasite burdens, and the quantity of cellular infiltrate, but significantly elevated serum levels of ALT, AST, and LDH. Low BNZ plus vaccine did not significantly affect hepatomegaly, parasite burdens or the quantity of cellular infiltrate, but only elevated ALT and AST. Low dose BNZ significantly decreased expression of both BTG2 and PPARα, and curative BNZ reduced expression of BTG2 while low BNZ plus vaccine had no impact. Conclusions These data confirm toxicity associated with curative doses of BNZ and suggest that while dose sparing low BNZ plus vaccine treatment does not reduce parasite burdens, it better preserves liver health.
dc.identifier.citationNguyen, D. M., Poveda, C., Pollet, J., Gusovsky, F., Bottazzi, M. E., Hotez, P. J., & Jones, K. M. (2023). The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLOS Neglected Tropical Diseases, 17(11), e0011519. https://doi.org/10.1371/journal.pntd.0011519
dc.identifier.digitaljournal-pntd-0011519
dc.identifier.doihttps://doi.org/10.1371/journal.pntd.0011519
dc.identifier.urihttps://hdl.handle.net/1911/115558
dc.language.isoeng
dc.publisherPublic Library of Science
dc.rightsExcept where otherwise noted, this work is licensed under a Creative Commons Attribution (CC BY) license. Permission to reuse, publish, or reproduce the work beyond the terms of the license or beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleThe impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpublisher version
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
journal-pntd-0011519.pdf
Size:
2.75 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications